Clinical Trial Update: Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of MK-3682B in participants with moderate to severe renal impairment for hepatitis C has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-3682B

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2018-12-14